Siegel Matthew A, Patetta Michael J, Chen Jason Y, Barragan Echenique Diego M, Gonzalez Mark H
University of Illinois College of Medicine at Chicago, Department of Orthopaedic Surgery, USA.
J Orthop. 2021 Apr 2;25:16-22. doi: 10.1016/j.jor.2021.03.018. eCollection 2021 May-Jun.
The custom triflange acetabular implant (CTAI) has been described to address catastrophic pelvic osteolysis, but long-term outcome data is scarce.
Revision-free survivorship after revision THA with a CTAI was retrospectively reviewed in seven patients.
Mean and median follow-up time were 7.39 (1.61-16.8) years and 7.50 years, respectively. Revision-free survivorship was 85.7% (6/7). One patient underwent revision for recurrent dislocations. All patients were able to ambulate at recent follow-up- 2/7 without assistance.
The CTAI is a viable option for patients with catastrophic pelvic osteolysis. There is a high complication rate, but the incidence of revision is low.
定制三翼髋臼植入物(CTAI)已被描述用于治疗灾难性骨盆骨溶解,但长期结果数据稀缺。
对7例接受CTAI翻修全髋关节置换术(THA)后的无翻修生存率进行回顾性研究。
平均随访时间和中位随访时间分别为7.39(1.61 - 16.8)年和7.50年。无翻修生存率为85.7%(6/7)。1例患者因复发性脱位接受翻修手术。所有患者在最近一次随访时均能行走,其中2/7无需辅助。
CTAI是治疗灾难性骨盆骨溶解患者的可行选择。并发症发生率高,但翻修率低。